377 related articles for article (PubMed ID: 18617601)
1. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin.
Kitamura S; Maeda K; Wang Y; Sugiyama Y
Drug Metab Dispos; 2008 Oct; 36(10):2014-23. PubMed ID: 18617601
[TBL] [Abstract][Full Text] [Related]
2. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
[TBL] [Abstract][Full Text] [Related]
3. Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin.
Hirano M; Maeda K; Matsushima S; Nozaki Y; Kusuhara H; Sugiyama Y
Mol Pharmacol; 2005 Sep; 68(3):800-7. PubMed ID: 15955871
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
5. The hepatobiliary disposition of timosaponin b2 is highly dependent on influx/efflux transporters but not metabolism.
Sheng J; Tian X; Xu G; Wu Z; Chen C; Wang L; Pan L; Huang C; Pan G
Drug Metab Dispos; 2015 Jan; 43(1):63-72. PubMed ID: 25336752
[TBL] [Abstract][Full Text] [Related]
6. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.
Yamashiro W; Maeda K; Hirouchi M; Adachi Y; Hu Z; Sugiyama Y
Drug Metab Dispos; 2006 Jul; 34(7):1247-54. PubMed ID: 16624871
[TBL] [Abstract][Full Text] [Related]
7. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.
Matsushima S; Maeda K; Kondo C; Hirano M; Sasaki M; Suzuki H; Sugiyama Y
J Pharmacol Exp Ther; 2005 Sep; 314(3):1059-67. PubMed ID: 15901800
[TBL] [Abstract][Full Text] [Related]
8. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
[TBL] [Abstract][Full Text] [Related]
9. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans.
Takeuchi K; Sugiura T; Matsubara K; Sato R; Shimizu T; Masuo Y; Horikawa M; Nakamichi N; Ishiwata N; Kato Y
Drug Metab Dispos; 2014 Apr; 42(4):726-34. PubMed ID: 24440960
[TBL] [Abstract][Full Text] [Related]
10. Understanding the interplay of drug transporters involved in the disposition of rosuvastatin in the isolated perfused rat liver using a physiologically-based pharmacokinetic model.
Hobbs M; Parker C; Birch H; Kenworthy K
Xenobiotica; 2012 Apr; 42(4):327-38. PubMed ID: 22035568
[TBL] [Abstract][Full Text] [Related]
11. Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism.
Tomita Y; Maeda K; Sugiyama Y
Clin Pharmacol Ther; 2013 Jul; 94(1):37-51. PubMed ID: 23443754
[TBL] [Abstract][Full Text] [Related]
12. Identification of the transporters involved in the hepatobiliary transport and intestinal efflux of methyl 1-(3,4-dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) glucuronide, a pharmacologically active metabolite of S-8921.
Sakamoto S; Kusuhara H; Horie K; Takahashi K; Baba T; Ishizaki J; Sugiyama Y
Drug Metab Dispos; 2008 Aug; 36(8):1553-61. PubMed ID: 18474677
[TBL] [Abstract][Full Text] [Related]
13. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.
Ho RH; Tirona RG; Leake BF; Glaeser H; Lee W; Lemke CJ; Wang Y; Kim RB
Gastroenterology; 2006 May; 130(6):1793-806. PubMed ID: 16697742
[TBL] [Abstract][Full Text] [Related]
14. Transport mechanisms of hepatic uptake and bile excretion in clinical hepatobiliary scintigraphy with 99mTc-N-pyridoxyl-5-methyltryptophan.
Kobayashi M; Nakanishi T; Nishi K; Higaki Y; Okudaira H; Ono M; Tsujiuchi T; Mizutani A; Nishii R; Tamai I; Arano Y; Kawai K
Nucl Med Biol; 2014 Apr; 41(4):338-42. PubMed ID: 24607436
[TBL] [Abstract][Full Text] [Related]
15. Establishment of a set of double transfectants coexpressing organic anion transporting polypeptide 1B3 and hepatic efflux transporters for the characterization of the hepatobiliary transport of telmisartan acylglucuronide.
Ishiguro N; Maeda K; Saito A; Kishimoto W; Matsushima S; Ebner T; Roth W; Igarashi T; Sugiyama Y
Drug Metab Dispos; 2008 Apr; 36(4):796-805. PubMed ID: 18180273
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
[TBL] [Abstract][Full Text] [Related]
17. Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver.
Pfeifer ND; Bridges AS; Ferslew BC; Hardwick RN; Brouwer KL
J Pharmacol Exp Ther; 2013 Dec; 347(3):737-45. PubMed ID: 24080682
[TBL] [Abstract][Full Text] [Related]
18. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein.
Huang L; Wang Y; Grimm S
Drug Metab Dispos; 2006 May; 34(5):738-42. PubMed ID: 16415124
[TBL] [Abstract][Full Text] [Related]
19. Role of transporters in the disposition of the selective phosphodiesterase-4 inhibitor (+)-2-[4-({[2-(benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic acid in rat and human.
Kalgutkar AS; Feng B; Nguyen HT; Frederick KS; Campbell SD; Hatch HL; Bi YA; Kazolias DC; Davidson RE; Mireles RJ; Duignan DB; Choo EF; Zhao SX
Drug Metab Dispos; 2007 Nov; 35(11):2111-8. PubMed ID: 17686907
[TBL] [Abstract][Full Text] [Related]
20. An experimental approach to evaluate the impact of impaired transport function on hepatobiliary drug disposition using Mrp2-deficient TR- rat sandwich-cultured hepatocytes in combination with Bcrp knockdown.
Yang K; Pfeifer ND; Hardwick RN; Yue W; Stewart PW; Brouwer KL
Mol Pharm; 2014 Mar; 11(3):766-75. PubMed ID: 24410402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
